Minerva Neurosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	1.44	-30.01	-32.11	-49.91	1.94	Upgrade
Depreciation & Amortization	0.01	0.01	-	0.1	0.18	Upgrade
Other Amortization	0.02	0.03	0.01	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	15.2	-	Upgrade
Loss (Gain) From Sale of Investments	-	-	-	-	-0.09	Upgrade
Stock-Based Compensation	1.33	1.97	4.11	5.22	9.7	Upgrade
Other Operating Activities	-22.02	8.28	7.41	4.52	-	Upgrade
Change in Accounts Payable	-0.2	0.84	-0.88	0.86	-1.32	Upgrade
Change in Unearned Revenue	-	-	-	-	-41.18	Upgrade
Change in Other Net Operating Assets	-0.12	4.1	-3.18	-0.6	-3.06	Upgrade
Operating Cash Flow	-19.55	-14.78	-24.65	-24.6	-33.82	Upgrade
Capital Expenditures	-	-	-0.02	-	-	Upgrade
Investment in Securities	-	-	-	-	24.53	Upgrade
Investing Cash Flow	-	-	-0.02	-	24.53	Upgrade
Issuance of Common Stock	-	20	-	-	13.69	Upgrade
Other Financing Activities	-	-0.4	-0	60	-0.46	Upgrade
Financing Cash Flow	-	19.6	-0	60	13.24	Upgrade
Net Cash Flow	-19.55	4.82	-24.66	35.4	3.94	Upgrade
Free Cash Flow	-19.55	-14.78	-24.66	-24.6	-33.82	Upgrade
Free Cash Flow Margin	-	-	-	-	-82.14%	Upgrade
Free Cash Flow Per Share	-2.58	-2.27	-4.62	-4.61	-6.61	Upgrade
Levered Free Cash Flow	-15.48	-12.69	-20.36	-17.08	6.83	Upgrade
Unlevered Free Cash Flow	-12.63	-7.51	-15.73	-13.13	6.83	Upgrade
Change in Net Working Capital	0.32	-4.94	4.06	-0.41	4.21	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q